Good morning and good afternoon, everyone, and welcome to Innate Pharma's IP event on IPH4502, Innate's Nectin-4 ADC. Today, we will discuss the initial data from its phase I dose escalation study, as well as the planned next steps. Thank you for joining us, and we look forward to the discussion. Before we begin, I would like to remind everyone that today's presentation includes forward-looking statements based on current expectations, and these statements involve risks and uncertainties that could cause actual results to differ materially. Let me briefly outline the program. Jonathan Dickinson, our Chief Executive Officer, will open with Innate pipeline, the main phase I key takeaway, and also the positioning of IPH4502 in the current Nectin-4 landscape. Yannis Morel, our Chief Operating Officer, will then explain IPH4502 design and scientific rationale.
We are very pleased to have Professor Yohann Loriot joining us today to provide clinical context on the treatment of advanced urothelial cancer and to review the phase I findings. Markus Jensen, our Chief Medical Officer, will then discuss the planned next steps and the potential development path. Jonathan will return with closing remarks before we open the event for questions. As a reminder, this is a phase I dose escalation study, signal seeking, and direct comparison versus other trials at different stages of development are not appropriate. Statements concerning future development reflect current plans and may change. Before we begin, I'd like to introduce Professor Yohann Loriot. Professor Loriot is a medical oncologist specializing in urothelial cancer at Gustave Roussy, where he serves as the deputy head of therapeutic innovation and early trials.
He is also a professor at Paris-Saclay University and leads the EORTC Urological Tumor Study Group. We are very pleased to have his expertise and clinical perspective as part of today's discussion. With that, I'll hand over to Jonathan.
Thank you, everybody, and welcome to today's IPH4502 event. We're very pleased to be able to share the first clinical findings for IPH4502 today and to discuss the observations which are basically informing the next steps for the program. Before focusing on 4502, what I'd like to do is just outline the overall context of Innate's pipeline. Innate's portfolio combines proprietary ADC programs, and that's combined with late-stage partnered assets, as you can see on the slide. IPH4502 is our proprietary Nectin-4 ADC, which is moving from dose escalation into dose optimization. Following the validation of our proprietary linker in the IPH4502 program, we continue to advance our next generation of ADCs in our pipeline, with the objective to bring meaningful innovation to the ADC field. Our partner programs also continue to advance and represent important near-term opportunities.
For lacutamab, partnered with Sobi, the first patient dosing in the phase III TELLOMAK-3 study is expected in the first quarter of 2027. This will facilitate the planned BLA filing for accelerated approval in Sézary syndrome in the second half of 2027, in alignment with our prior FDA discussions. For monalizumab, our partner AstraZeneca is conducting the PACIFIC-9 phase III trial in non-small cell lung cancer. The high-level readout for the primary endpoint is currently expected in the first half of 2027. Today's event is dedicated now to IPH4502. The first phase I dose escalation data provide the basis to move forward into dose optimization in urothelial cancer post-EV. With the first phase I dose escalation data now available, I would like to highlight three important study findings. First, IPH4502 is well tolerated through dose escalation, with low overall hematologic toxicity. This is consistent with the minimal free circulating payload.
Importantly, this validates the stability of our linker. The maximum tolerated dose was 3.6 mg per kilogram, administered every three weeks, with stomatitis as the only reported dose-limiting toxicity. Stomatitis is a known adverse event common to many Topo1 ADCs, and there are several successful mitigation precedents to manage this adverse event. Second, we are encouraged by the anti-tumor activity observed in the heavily pre-treated patient population recruited in the dose escalation study. We have seen clinical activity across multiple dose levels and multiple tumor types. At the maximum tolerated dose of 3.6 mg per kilogram, an objective response rate of 33% was observed among six patients with non-urothelial cancers, with one confirmed CR and one confirmed PR. Importantly, we also observed clinical activity in patients with urothelial cancer post-EV at intermediate dose levels, with an unconfirmed disease control rate of 68%.
In addition, we also saw clinical activity in other tumor types with low, moderate, and high levels of Nectin-4 expression. Interestingly, this included two confirmed PRs in non-small cell lung cancer out of four patients enrolled in this indication. Third, taken together, these clinical findings provide an encouraging foundation for further clinical investigation with a clear, focused go-forward development strategy. The next step is phase I dose optimization in urothelial cancer post-EV. Our aim is to characterize clinical activity at the upper dose levels in UC post-EV, reduce stomatitis by implementing a split dosing regimen and mandatory stomatitis prophylaxis, with the aim to identify an appropriate recommended phase II dose and schedule. Before we move into the clinical data, I would like to briefly touch the evolving competitive landscape and highlight the differentiative positioning of IPH4502.
On the left of the slide, you can see that Nectin-4 ADCs are evaluated in urothelial cancer and across a broad range of tumors, including cervical, head and neck, and lung. For IPH4502, our initial focus is urothelial cancer post-EV, where we see a particularly interesting opportunity for Nectin-4 Topo1 ADCs, which carry a different payload versus EV. The Topo1 payload has the potential to overcome resistance to MMAE and meet a high unmet medical need. Professor Loriot will discuss this later. On the middle of the slide, we can see that to date, the asset from Lilly and IPH4502 are the only two Nectin-4 Topo1 ADCs with reported clinical activity in UC post-EV. Lilly presented data at ASCO 26, reporting a 33% response rate in post-EV patients during dose optimization, providing an encouraging clinical signal for the Topo1 approach.
However, their program carries a CYP2D6 liability that mandates genotyping of all patients prior to treatment. For IPH4502, we observed anti-tumor activity in UC post-EV already during the dose escalation phase, and as previously described, we are moving into the dose optimization initiation. Importantly, IPH4502 does not require patient genotyping. Finally, PADCEV has already demonstrated the commercial opportunity of Nectin-4 targeting, with approximately $2 billion in worldwide annual sales in 2025 and approvals across multiple urothelial cancer treatment settings. The initial go-forward strategy is to focus on urothelial cancer post-EV while retaining the potential to expand into other indications over time. I will now hand over to Yannis to remind you of the scientific rationale behind IPH4502. Yannis.
Thank you, Jonathan. I would like now to present the key attributes of IPH4502 and explain why we believe this design is differentiated and merits further clinical investigation. Next slide, please. We have designed IPH4502 by bringing together an exatecan payload, a proprietary stable linker, and a proprietary Nectin-4 targeting antibody. Each component was selected with a particular development objective in mind. Starting with exatecan, this topoisomerase I payload differs from the MMAE used in the enfortumab vedotin by its mode of action. Also, it has bystander killing as well as low sensitivity to MDR1 efflux pump, which is described to be a key mechanism of resistance to MMAE, therefore providing rationale to investigate IPH4502 in patients previously treated with EV. Exatecan is cleared through CYP3A4 metabolism, as opposed to [COMP98] that requires CYP2D6 genotyping for patient selection.
Our proprietary linker was designed to remain stable in circulation and allow relatively slow release of free exatecan in order to help limit systemic payload exposure, with possible implication for better tolerability. Finally, the antibody recognizes a differentiated epitope on Nectin-4 and has high internalization capacity. We believe this feature supports further investigation in tumors with low or heterogeneous Nectin-4 expression. Taken together, this design provides potential points of differentiation, and we are eager to see how the phase I findings begin to tell us how this molecule behaves in patients. For the clinical landscape and those initial results, I am pleased to hand it over to Professor Loriot.
Good morning and good afternoon, everyone. Thank you. I will now review the current treatment landscape in metastatic urothelial cancer and then discuss, as mentioned earlier, the phase I clinical finding generated with IPH4502. Next slide, please. EV plus pembrolizumab, as you know, now is a frontline standard of care in advanced urothelial cancer, and that has produced unprecedented survival outcome with response rate around 65%-70%, and durable response in many patients. However, there are two important observations. Number one, around 1/2 of responding patients have progressed or died by two years. Number two, treatment-related toxicity, and especially neuropathy, remains clinically meaningful with over one-third of patients ultimately discontinuing enfortumab vedotin because of adverse events, so skin toxicity or neuropathy. When patient experience disease progression after EV-based therapy, there is currently no established standard of care.
In daily practice, in real-world practice, most patients receive platinum-based chemotherapy, which typically delivers response rate around 20%-40%, but the median duration of response quite limited, three to four months, and overall survival below one year for most patients. Therefore, there remains a significant need, of course, for additional treatment option in the post-EV setting. Next slide. To explore the potential of IPH4502, we conducted an open-label phase I dose escalation study in advanced solid tumors known to express Nectin-4. This is a classical first-in-human trial designed to evaluate safety, tolerability, pharmacokinetics, of course, and preliminary anti-tumor activity. Patients were heavily pretreated and had exhausted available standard therapy, and importantly, prior EV exposure was allowed for patients with metastatic urothelial cancer.
A total of 76 patients were enrolled across six dose levels, ranging from 0.6 mg per kilogram to 3.6 mg per kilogram, given every three weeks using a BOIN dose escalation design with backfilling cohorts. The primary objective were safety, tolerability, and of course, the determination of the MTD, while efficacy assessments remain currently exploratory and signal-seeking. Next slide. Thank you. The study enrolled a heavily pretreated population, as I mentioned earlier. A patient had received a median of three, half p rior lines of systemic therapy, and a half had received at least four prior treatment lines. Looking specifically now at the urothelial cancer cohort, all patients had previously been treated with enfortumab vedotin. Nearly all had received platinum-based chemotherapy, and all had received prior PD-1 or PD-L1 therapy. Importantly, enrollment was not restricted by Nectin-4 expressions.
Around 1/3 of patients were Nectin-4 negative, while the remaining patients were distributed across low, moderate, and high expression categories. This allow us to begin exploring activity across the full spectrum of Nectin-4 expressions. Next slide. This was a broad signal-finding study involving more than 10 tumor types. As you can see on this slide, urothelial cancer represent the largest individual cohort with 19 patients, followed by head and neck cancer and colorectal cancer. For the urothelial cancer populations, most patients were treated at the 2.4 mg per kilogram and 2.8 mg per kilogram dose level, with four patients treated at 3.2 mg per kilogram. Importantly, no urothelial cancer patient was treated at the 3.6 mg per kilogram dose level. This point is important when interpreting the efficacy outcome because the highest activity signal were observed at the upper dose levels. Next slide. Turning first to safety.
IPH4502 was generally well tolerated throughout dose escalation, and the maximum tolerated dose was established at 3.6 mg per kilogram every three weeks. The only DLT, so the dose-limiting toxicity observed, was stomatitis, which is a recognized class effect for several Topo1 ADCs. Several aspects of the safety profile here deserve some attention. Number one, hematologic toxicity was relatively limited. We observed no febrile neutropenia and no hematologic dose-limiting toxicity, which is a very important point. Number two, skin toxicity were uncommon, and as you know that with EV, one important toxicity is skin tox. Here, with the IPH4502, the skin toxicity were uncommon, and importantly, we did not observe a signal for peripheral neuropathy, which remains a clinically relevant issue with the MMAE-containing ADC like enfortumab vedotin. Treatment discontinuation due to adverse events occur in only 5.3% of the patients.
Overall, the emerging safety profile appears manageable and, of course, supports continued clinical development. Next slide, please. Although efficacy assessment remains preliminary, anti-tumor activity was observed across multiple dose levels and across different tumor types. A dose response trend appears to be emerging, with objective response rate increasing at higher dose levels and reaching up to 33% at the 3.6 mg per kilogram dose. Importantly, responses were observed not only in urothelial cancer, but also across several additional tumor types. Given the heavily pretreated nature of this population and the exploratory intent of the study, this data provide encouraging evidence that the molecule is biologically active. Next slide. Another interesting observation that we did concerned the Nectin-4 expressions. Responses were not confined to patients with high target expressions. You can see here an example on this slide.
The example shown here illustrates meaningful tumor shrinkage across low, moderate, and high Nectin-4 expression categories. Of course, this data remain preliminary and involve small numbers of patients, but they are consistent with the hypothesis that IPH4502 may retain activity across a broader range of target expression level than might traditionally be expected. Of course, this observation will require confirmation in larger dataset, but represent an important area of ongoing investigation, of course. Next slide. The PK findings may explain some aspect of the safety profile. At the 3.6 mg per kilogram dose level, free exatecan concentration in plasma remain relatively low compared with the total antibody exposure. This pattern is consistent with slow systemic payload release and support clearly the stability of the linker technology.
From a clinical perspective, lower systemic exposure to the free payload may contribute to the relatively low hematologic toxicity observed during the dose escalation phases. These PK findings are preliminary, but they align with the intended design characteristic of the molecules of the IPH4502. Next slide. To summarize, IPH4502 has been evaluated in 76 heavily pretreated patients across more than 10 tumor types so far, including a cohort of urothelial cancer patients previously treated with EV. The molecule demonstrated a manageable safety profile with stomatitis at the only dose-limiting toxicity and relatively limited hematologic, skin, ocular, and neurologic toxicity. Preliminary anti-tumor activity was observed across multiple dose level, with objective response seen in post-EV urothelial cancer, as well as in several additional tumor types. Importantly, as I mentioned earlier, responses were observed across low, moderate, and high levels of Nectin-4 expression.
Taken together, these findings suggest that IPH4502 warrants continued development, and they provide the foundation for the next phase of the dose and schedule optimizations in post-EV urothelial cancer that we will describe in a minute. Thank you.
Excuse me, Markus, you're muted.
No, I'm unmuted. I'm sorry for that. Thank you, Professor Loriot, for reviewing the treatment landscape and walking us through the phase I results. I'd like now to build on those findings and to explain the rationale for the next steps of the drug development. Our immediate question is how to optimize the dose and schedule in a more focused post-EV urothelial cancer population. Next slide. This slide connects the design principles Yannis described earlier with what we have actually observed in the clinic. We have seen objective responses in patients with urothelial cancer previously treated with EV. We have seen objective responses across low, moderate, and high Nectin-4 expression levels. We have also observed low circulating concentrations of free exatecan alongside with low overall hematologic toxicity. We can conclude today that this data support further clinical evaluation of IPH4502.
The next stage is intended to inform selection of a recommended phase II dose and schedule in post-EV urothelial cancer based on safety, PK, and anti-tumor activity data. Next slide, please. One of the observations informing our strategy comes from the pharmacokinetic analysis. The chart shows dose-normalized exposure is higher at 3.6 mg per kilogram versus 3.2 mg per kilogram, so at the upper end of our dosing. Our hypothesis is that this is consistent with Nectin-4 target saturation, with an excess of ADC circulating in the bloodstream and not entering the cancer cell. It provides a rationale for further investigating dose and schedule. Instead of delivering the full planned dose on day one, we want to split the dose with the objective of reducing stomatitis while maintaining efficacy, as this has also been done previously with other ADCs. The next slide.
There is precedent for dividing dose schedules with ADCs.
The reasons for and the results of those schedules may differ by molecule. The diagram on the left illustrates the principle we want to investigate. Dividing a dose may reduce the peak concentrations while maintaining the overall exposure, because the same amount of drug is given. It's a schematic illustration, not a measured PK results for IPH4502. The examples on the right include examples of ADCs that use such a split-dose regimen. PADCEV is the only approved Nectin-4 ADC, is administered as monotherapy on day one, eight, and 15 in a four-week cycle, and in combination with pembrolizumab on day one and eight of a three-week cycle. Other ADCs targeting different tumor antigens also use split dosing.
These include TRODELVY, administered on day one and day eight of a three-week cycle, and iza-bren, which is approved in China and is also administered on day one and day eight of a three-week cycle. For our program, this is supportive rationale for a prospective clinical evaluation. We need to establish whether a split dose can reduce stomatitis while sustaining relevant exposure and anti-tumor activity. The next slide. Our proposed next step has three related elements. First, dose and schedule. In the completed dose escalation portion, IPH4502 was administered on day one every three weeks, and the maximum tolerated dose was identified as 3.6 mg per kilogram. We now plan to explore dosing on day one and eight of each three-week cycle. We will evaluate dose around the prior maximum tolerated dose, and if emerging data support it, potentially to a slightly higher dose per cycle.
Second is the stomatitis prevention. Prophylaxis was recommended and introduced during the recruitment of the 3.6 mg per kilogram dose level. In the next stage, we plan to make prophylaxis a mandatory element and using measures such as steroid-containing mouthwash, oral hygiene, and cryotherapy, informed by the experience of other ADCs. Third is patient selection. Our first study enrolled patients across multiple tumor types, and relatively few UC patients received the highest doses. We now plan to focus on post-EV urothelial cancer in the second line or later setting. The initial UC cohort has received a median of three prior lines of systemic therapy. Together, these steps are intended to inform selection of a recommended phase II dose and schedule in line with the principle of dose optimization. Next slide. This slide now outlines our indicative development sequence, which remains subject to clinical results and regulatory feedback.
We anticipated dose and schedule optimization in post-EV urothelial cancer during 2027 and 2028. The key objective will be to select a recommended phase II dose and regimen based on emerging safety, PK and activity data. If those findings support further development, our plan is to start with phase II/III evaluation from 2028 onward. Over time, we may also explore earlier UC setting combination with immunotherapy or selected other tumor types. Our immediate priority is to characterize IPH45 in post-EV UC and determine the optimal dose and schedule. With that, I'll hand back to Jonathan.
Thank you, Markus, and thank you again to Professor Loriot for sharing his clinical perspective. Before we take questions, I'd like to just return to the central messages from today's presentation. The first data from the phase I dose escalation study has provided an important dataset. A well-tolerated safety profile has been characterized. The maximum tolerated dose has been established, and anti-tumor activity has been observed in a heavily pre-treated patient population, including patients with urothelial cancer who had received EV. The results define a clear clinical development path to progress IPH4502. Stomatitis was the only reported dose-limiting toxicity, which we aim to mitigate by implementing a split dose schedule and mandatory prophylaxis, which is based on successful historical precedence. With these measures, the aim is to overcome the stomatitis DLT and thereby unlock dosing levels equivalent to the 3.6 mg per kilogram dose or higher.
The dose optimization will generate data in a focused UC patient population, potentially at higher equivalent doses versus those evaluated in the initial dose escalation. The first dose finding data support continued disciplined clinical evaluation of IPH4502. The next clinical objective is to identify the recommended go-forward phase II dose and schedule for urothelial cancer post-EV. Thank you for your continued interest in IPH4502, and we would now be pleased to answer your questions. I think we have the first one in the room from RK from H.C. Wainwright.
Yeah, this is RK from H.C. Wainwright. Thank you, Jonathan, for this event and also the data, obviously, and very interesting, and congratulations. As you folks suggested, and the data suggests, stomatitis is the only dose-limiting toxicity at this point, and it certainly hit all patients who were dosed at 3.6 mg per kilogram. When you're thinking about splitting the dose in the next phase of the study, outside of stomatitis, is there a concern in terms of just the PK, or also you were trying to see if you can get a totality of dose higher than 3.6 mg per kilogram?
I think I'll let Markus answer that question. Maybe I can give a quick intro. I think we would like to be able to get to higher doses and potentially unlock greater efficacy, but Markus is the expert on this, and I think he should give the very scientific answer.
Yeah, a couple of points. We have seen 3.2 mg per kilogram and 3.6 mg per kilogram coming with encouraging clinical activity. That is what we want to further investigate. These two doses are already interesting, and if we split them, we would then have the same amount of drug per three-week cycle that is given and has a chance to enter the tumor cell to kill the tumor cell. That's why there is, in principle, the assumption that the efficacy is preserved, and there are examples from other studies where this was also shown. If the safety is getting better, and we have presented why we are confident that we have a good concept to get the safety even better at the upper end, then what we are going to do is, of course, not blocking at a 3.6 mg per kilogram split, but allowing something slightly higher.
But of course, in a very cautious way, because patient safety rules anytime. But yes, we can go a bit higher. This all is subject of discussion with the health authorities, and the amendment is almost ready, and we will have this discussion then very soon.
Can I get one more question?
Yeah, absolutely.
So when you look at the bladder cancer patients, all 19 of them were treated below the top dose. But in the patients who responded, or the responder patients, what was their experience with PADCEV in terms of the length of PADCEV treatment? Are the responders those who had a shorter period of PADCEV experience compared to the non-responders?
I will let Markus answer that question as well.
All 19, as already said, had PADCEV, and the PADCEV exposure was usually quite significant. It is not just one dose and then they switched the drug. We have not presented statistics here, but the vast majority of patients had many cycles. So the resistance is assumed to, let's say, clinically relevant level. The activity, therefore, is something we analyzed per dose level. We did not find a correlation of dose level and activity concerning the PADCEV history of the patients. This was not visible in the data. The patients with urothelial at the lower doses, well, we said intermediate doses, starting at 2.4 mg per kilogram, they had quite systematic shrinkage of the tumor, although to a bit limited extent at that dose level. Then with the higher dose level, they did a little bit this and that.
The best explanation we found in the data is that this is just by random, because at the end of the day, the number of urothelial per dose level is not very high.
Thank you.
Further questions in the room? Yeah. Maybe, I think we have some from the line.
Yeah. We have several questions from the line. First question, David Thompson from Biota. "How would you compare this dataset with the presentation from Lilly at ASCO?
Yeah. Maybe I would take that one. I think it's a very difficult comparison to make. If you think of the stage of the study we've just done, we've done a dose escalation study. The Lilly data that was presented at ASCO was a dose escalation and dose optimization dataset. So they had completed the next step that we're about to move into, where they had basically moved forward in urothelial cancer and recruited, I think, over 100 patients to characterize their go-forward doses. Just to remind you, the objective of the dose escalation study is to establish the safety of the product. It's to establish the PK of the product and to look for signal detection. And I think that's exactly what we've demonstrated in our dataset. We've shown, I think, a well-tolerated ADC that we believe we can take forward into the next steps.
We've seen responses in multiple tumor types across varying levels of expression of Nectin-4, and I think we focus and hone in now on, I would say, the most obvious next step, which is to go into urothelial cancer post-PADCEV, where there's a very high unmet medical need, where we can then further characterize IPH4502. Thank you for the question.
In person, another question, more on the safety. "What were the adverse events that led to withdrawal of the drugs or reduction of the dose?
Markus, maybe I'll let you take that one.
Yeah, sure. We have four patients where the drug was permanently withdrawn due to adverse events, and these were three patients with stomatitis, and it was one patient with anemia, all grade 3. The stomatitis withdrawals were at the highest dose, 3.6 mg per kilogram, and there was one at 2.8 mg per kilogram, and the anemia was also at 2.8 mg per kilogram. The dose reduction, which talks in that way to the drug that it shows that a patient can maintain an intended dose level, is also very important. And we have six patients where the dose was reduced one or several times in a few cases, and it was one at the 2.4 mg with a maculopapular rash, grade 3. Then we have one patient at 2.8 mg per kilogram with slight AST elevation, grade 2.
There was three patients at 3.2 mg per kilogram, one with anemia and neutrophil count decrease, one patient with a pneumonitis, which was a lung cancer patient post-irradiation. And then there was one patient at 3.2 mg per kilogram with a lot of grade 1 and grade 2 events, and the sum was then reason for reducing the dose. It was fatigue, dysgeusia, vomiting, diarrhea, and epistaxis was listed in the data. And there was one patient at 3.6 mg per kilogram with a dose reduction that was stomatitis and esophagitis in a combined setting. This is the full list of events for—
Thank you, Markus.
Thank you, Markus. Now we have a question from Daina Graybosch from Leerink Partners. The first one is, "Help us understand why there is a step-up in exposure in the 3.6 mg per kilogram from relatively flat exposure across 1.2 mg per kilogram - 3.2 mg per kilogram." There are several.
Markus.
That goes to me again, yeah. First to say that there is a step-up, this was not fully predictable. But when we see it's understandable, because the effect that if we give a drug that binds a target, when the target is saturated, the concentration is going up, is something we see with many drugs that's so-called TMDD effect. It's nothing strange. That we see it at 3.6 mg per kilogram is what we learned in the study. That is the explanation. The data shows that there is also space between 3.2 mg per kilogram and 3.6 mg per kilogram. Maybe this is something that is to be said in addition.
The AUCs of the patients at 3.6 mg per kilogram, they have enough distance to 3.2 mg per kilogram that we can really investigate if the data tells us in the next step doses around 3.6 mg per kilogram, which gives us great flexibility what we are planning to do now.
We can go in between, we can go to 3.6 mg per kilogram split, we can go a bit higher.
Okay. Still from Daina Graybosch, "Will the dose optimization randomize patient to split and regular dose schedule, given the practical benefit of a regular Q3 week dosing and the potential positive impact of prophylaxis mouthwash?
Yeah. These are three questions. Hold on. Starting with the mouthwash, this is something that is established for other drugs, for example, Dato-DXd, and we use what is established in the practice. That is steroid-containing mouthwash with an antifungal, because it is given over a bit longer period to avoid fungal infections. That is then ice chips on the day of infusion to reduce the mucosal blood flow, and then a bunch of supplementary measures like recommendations for what they can eat, careful mouth hygiene, and some other things that sometimes come also from local care, which is then allowed. The acceptance of day one, day eight, we have spoken with our investigators, and there was never a comment that this is a problem. It is obviously something that can be done. It is done for EV, it is done for iza-bren, for example. We mentioned these two.
Why is this okay? Because often the patient has to come back for general safety and medical reasons anyway, so that there are not too many visits at the end of the day. I do not have exact quantification. Of course, this would mean study of real life. But in principle, this is nothing that had, let us say, resistance in the discussions we had with the site. Now I need to ask the first question. What was the first question?
Maybe we can get Professor Loriot to comment on the day one, eight versus the Q3 week, because I think from a practical perspective.
Yes, indeed. For metastatic urothelial cancer, a day one, day eight schedule every three weeks is generally acceptable, especially in later line patients. Markus mentioned that that is something we are using in daily practice. Sacituzumab govitecan is given day one, day eight, every three weeks. Enfortumab vedotin is given every day one, day eight, every three weeks when combined with pembrolizumab. Many chemotherapy regimens used in urothelial cancer have included weekly components with Gemzar, paclitaxel, and so it is not a problem for patients to accept the day one, day eight. Regarding the investigator, the majority of the investigators accept this regimen, especially because stomatitis is substantially reduced with the use of SG, for example, and dose intensity is maintained or increased, and so the response rate can improve versus the Q3 weeks dosing.
It is not a problem in daily practice for the majority and the vast majority of the regimen that are using this kind of schedule.
I also recall some data based on usage in the office-based setting in the U.S., where there is a preference from office-based physicians for day one, for split regimens, where the patients come back more frequently. I think there is some payment associated with treatments in the U.S. market, which I think has implications as well for the usage of drugs like this. The final part of the question for Markus was , Stéphanie?
I repeat the question entirely from Daina Graybosch. Will the dose optimization randomize patients to split and regular dose schedule, given the practical benefit of regular dosing and the potential positive impact of prophylaxis mouthwash?
Yeah. The randomization, the next part is not planned as a randomized, but it's planned as a non-randomized dose optimization. This is possible, and at the end, the acceptance depends on the data and the benefit we do to improving the drug in the eyes of the health authorities at the end. Approximately one-third of the ADCs that were reviewed by the FDA over the last one or two years, and we did a research there, was with a non-randomized set. We can do it, and it can be accepted. At the end, the data counts. If the data is good, then we have a good situation. Our plan, I think, is a strong one, and we can easily go with a non-randomized setting, which gives us a greater control and flexibility over the split dose.
Okay. From Daina Graybosch at Leerink, what is the median follow-up across the dataset of the 15 patients ongoing on treatment? Could they compare from stable disease to responses? When should we expect report on durability?
Markus?
Yeah, we have, since August cutoff, we have one more response that's mentioned on the slides. This was the 22%. This is still data verification is ongoing. I don't have this mean response duration data. When does it come? When the data comes. I can't give you the number.
I think maybe one thing to add, Markus, is maybe you do have the response, the length of response of the responders in the 3.6 mg per kilogram dose.
Their treatment was well advanced when we have the data cut off, and so their response duration, that's what we calculated recently, was six and eight months.
Okay.
Okay.
Should we go to the next question?
Last question from Daina. Is there an association with exposure and toxicity and Nectin-4 expression?
Sorry, this was shortly interrupted. Can you reread?
Is there an association with exposure and toxicity and Nectin-4 expression?
With the Nectin-4 expression, we did not see an association with toxicity. The Nectin-4 expression in the mucosa, and there is some, is a physiologically regulated expression level, which should be independent from the deregulated Nectin-4 expression level in the cancer tissue. And we did not see any correlation between these two and the tox.
Okay. No, yeah. So, the question was really, is there an association of exposure and/or toxicity with the baseline Nectin-4 expression?
Exposure. This would be part of a modeling analysis, which is not yet there. And it would, at the end of the day, be more maybe a granular effect, if at all. From the tables we have and from the non-compartmental PK, we do not see anything.
Okay. Any impact on the dose optimization from this modeling?
Not really. We have modeled the exposure curves for the split dose, for the dose optimization part. We have these predictions, and they were part of the planning now. Yeah, everything's straightforward here.
Okay. Thank you, Daina, for the question. Now we have a question from Jeet Mukherjee from U.S. Bancorp BTIG. "Can you clarify how many UC patients that achieve response are still in response and on therapy, and what is the median follow-up? Can you provide further details on which dose will be evaluated for dose optimization?
Yeah. The urothelials, they are The responders are all now terminated. I don't have the calculated duration of response at the moment. We work with a kind of top-line data set from August. This is not the final data set at the end of a study, so there is something that comes later. That was the first one.
Yeah.
The second one, can you repeat the second one?
Yeah. The second one is about further detail on which doses will be evaluated for dose optimization.
Yeah. I think I partly answered that already. The 3.2 mg per kilogram and the 3.6 mg per kilogram is what we plan to split, and we have rules to be flexible enough to really optimize this split dose by going in between or higher.
Okay. Now we have a question from Charles Wallace from H.C. Wainwright. I will ask the question one by one. The first one, "Did prior Topo1 ADC exposure affect clinical response?
There's nothing we saw in that direction.
Okay. "Do you see that a payload cross-resistance, that as a payload cross-resistance, and with dose" No, we don't have this. It's not necessary. The second question, "Two out of four NSCLC patients responded. Are those responses confirmed and still ongoing, and is there room for a lung arm in the dose optimization, or is NSCLC a partner-funded indication?
The four, they are completed.
And they're all confirmed, I think, aren't they? They were confirmed responses.
Confirmed and completed. There is nothing open, yeah.
Yeah.
An additional arm as part of the dose optimization makes not much sense, because when we play now with dose and schedule to really find the optimal sweet spot, we do it in one tumor. What we would definitely do once we think the decision for opening up to second indication or third indication is right, we would certainly try to go down that path.
Yeah. I think you definitely see a signal in lung cancer. It's a small number of patients, but it's a very interesting signal. I think our priority is urothelial cancer and to go into urothelial cancer post-PADCEV at first. But when we come to the point of looking at a subsequent tumor type, clearly lung would be one of the tumor types that you would need to look carefully at. It's a very competitive space. Again, I think if we were looking at that might require a partnership to be able to do that with a significant lung player. If we're sticking with urothelial cancer, again, this is something that we're very capable of doing on our own without having a partner involved. I think there's some of the considerations and decisions we'll have to make as we move forward. Okay.
A question from Clemence Thiers from Stifel. "On the 76 patients treated, 68 are available for efficacy on the waterfall chart. What are the reasons for exclusion?
They are not excluded. This is just how it is done. The patients sometimes do not receive their first follow-up CT because they drop out for maybe clinical deterioration and progress or maybe other reasons. This is why not all 76 have a second CT, and therefore do not appear in the waterfall plot. The response rate, the objective response rate, follows the ITT principle, which means those without a second CT are considered for the denominator. So they are not hidden.
Okay. Another question from Independent. "What are the example of split dosing that may help reducing stomatitis or maintain activity?
A good example is the BHV-1510 poster that was presented last year.
Maybe we can pull the slides.
Yeah. We have that actually. This is a topo I, TROP-2 , which is like other topo I, TROP-2 known for causing stomatitis. This is the result that was shown on the poster. There was a nice We have to be correct, lower numbers. It is, of course, not a direct randomized comparison or so. But when splitting the dose, the all-grade stomatitis came down, and the grade 3 and higher came down in a quite obvious way. This is a good example. There is another one where the dose could be better maintained, but we don't have a slide here. This is about the question of efficacy. This is iza-bren, where the dose was splitted from 5 mg per kilogram to two times 2.5 mg per kilogram, and there is almost no change in efficacy in this trial.
This is an example that efficacy can be maintained. The general assumption is that efficacy always sticks close to the AUC, respectively the average concentration, which is technically unchanged if we split the dose, because the same amount of drug, as already said, is still given over three weeks.
Okay.
Okay. Another question from Independent. "Other Nectin-4 developers have implicated a biological link between Nectin-4 and HPV. To this point, can you comment on the HPV status in your head and neck and cervical patients, particularly those with objective response or tumor reductions?
Yeah. We have HPV data collected, and we do not see at the moment this difference that was described between HPV positive and negative. I cannot confirm this as a trend, but we have limited data, and therefore this is also not enough to say there is no trend if we would systematically investigate it in a larger trial. But we don't see a difference at the moment.
Okay. There is no further question.
I think we have another question in the room. RK from H.C. Wainwright.
Yeah. Thanks for allowing me to do a follow-up question here. I understand from the poster that all the responders had come across different exposures of, I mean, different expression of Nectin-4 levels. However, from the poster, it looks like there is one responder at the top dose was actually Nectin-4 negative.
I think there is a very specific reason behind this. Markus, maybe you want to explain this one.
Yeah. What we observed is that this patient responded quite nicely, and our biopsy shows it is negative, which is very, very low level expression at the end of the day. It is not zero, but it is close to zero. If we have 100% representative biopsy with one biopsy site is also a question that is always open with a single patient. What we saw is very low expression and very nice response. The response at 3.6 mg per kilogram, and the numbers is limited. It is a bit subjective, but they were dramatic because they came really after the first two infusions. The first CT showed very dramatic shrinkage. This was impressive at 3.6 mg per kilogram.
Yannis, if you wanted to add anything?
No, I think, Markus pointed toward the question of heterogeneity. It is a single patient, so I think we need to accumulate a bit more data, and to also understand a bit more the sensitivity of our assay.
Yeah, I was just wondering whether it is a payload spillover situation or is it really a biopsy situation?
I think it's too early to tell.
Yeah. Okay. Any more questions in the room? Okay. Then thank you everybody for your attendance and your interest in IPH4502, and we look forward to updating you further as we move through the next steps into dose optimization. Thanks, everybody.
Thank you.
Thanks very much.